Welcome to ChemoFree.com

This webpage discusses possible treatment options for NMIBC (nonmuscle invasive bladder cancer) for you to consult with your doctor.

Be sure to review all safety information included within.

Older man with white hair and a white moustache, lit in purple and pink, looking straight at the camera.

Not an actual patient.

This fight is personal. So is what comes next.

Treatment decisions are personal

I’m doing everything I can in my fight against bladder cancer.

When you're facing a certain kind of bladder cancer, treatment decisions are personal. And if your cancer hasn’t responded to Bacillus Calmette-Guérin (BCG) treatment or has come back, you want to know what’s next.

ANKTIVA is an FDA-approved, chemo-free immunotherapy used with BCG to treat adults with nonmuscle invasive bladder cancer (NMIBC) that hasn’t responded to BCG.1 Important Safety Information

How does it work?

Understand the Science
Older man with a white beard looking upward, lit in purple and pink light.

Not an actual patient.

I’ve had BCG. I’ve got questions.

Starting with, what’s next for me?


BCG is commonly used to treat certain types of bladder cancer. But sometimes cancer doesn’t respond to treatment or comes back afterward.2

If that’s happened to you, it’s important to know there may be other treatment options to discuss with your urologist.

Treatment options

  • Immunotherapy

    Helps your body’s immune system recognize and attack cancer cells. Different immunotherapies help the immune system fight cancer in different ways.

  • Chemotherapy (Chemo)

    Uses medicines to kill fast-growing cancer cells or stop them from growing. But chemo can also damage healthy cells that grow quickly, which may cause side effects.

  • Surgery

    Removes cancer from the body. For some people with high-risk bladder cancer that hasn’t responded to BCG, doctors may recommend surgery to remove the bladder. This is called a cystectomy.

  • Clinical Trials

    Research studies that test new treatments to see how well they work and how safe they are. Some may offer access to treatments not yet approved.

Woman with short hair, round glasses and hoop earrings looking up and to the side, lit in purple and blue light.

Not an actual patient.

My next step?

Get to know ANKTIVA.

ANKTIVA is a chemo-free immunotherapy that works with BCG to activate important immune cells to help fight certain types of bladder cancer. If you’ve been treated with BCG, treatment with ANKTIVA will be familiar.

Important Safety Information

What are the results?

Explore the Evidence

BCG started the fight.

ANKTIVA brings more to it.

Your immune system has cells that help recognize and attack cancer. ANKTIVA works with BCG to help activate those cells.

Important Safety Information

Two immunotherapies working together. Help the immune system fight bladder cancer (NMIBC).

  1. 1 BCG Helps start an immune response in the bladder.
  2. 2 + ANKTIVA Activates certain immune cells and increases their numbers.

If BCG didn’t work before, why use it again with ANKTIVA?

ANKTIVA works differently from BCG. Together, they offer another treatment approach for patients whose cancer hasn’t responded to BCG alone.

Meet some of your immune system’s defenders.

  • Microscopic rendering of a natural killer cell, a spiky sphere in yellow and green.

    Natural killer (NK) cells

    These cells can find and attack abnormal cells, including certain cancer cells.

  • Microscopic rendering of a CD8-positive killer T cell, a spiky sphere in blue and teal.

    CD8+ killer T cells

    These cells can recognize and destroy cells that show signs of cancer.

  • Microscopic rendering of a memory T cell, a spiky sphere in purple and violet.

    Memory T cells

    These cells help your immune system remember threats it has faced before. ANKTIVA activates these cells and increases their numbers.

Older man with white hair and blue eyes looking at the camera, lit in blue and pink light.

Not an actual patient.

I want to know what’s possible.

When it comes to your treatment, you want more than promises. You want to know what the research has shown.

Show me the results.

A clinical study is a research study involving people that helps researchers understand how well a treatment works and how safe it is. The QUILT-3.032 clinical study tested ANKTIVA + BCG in adults with high-risk nonmuscle invasive bladder cancer (NMIBC) — cancer that has not grown into the muscle of the bladder wall — that had not responded to BCG treatment.1

Clinical trial results

Illustration of the inside of a bladder: a flat red area of carcinoma in situ on the lining and a papillary tumor growing outward from the lining in a fingerlike shape.

All patients in the study had carcinoma in situ (CIS), a type of high-grade NMIBC that grows as a flat area on the bladder’s inner lining. Some patients also had papillary tumors, which grow outward from the lining in fingerlike shapes.1

Patients received ANKTIVA + BCG once a week for 6 weeks. Some could receive another 6 weeks of treatment starting at month 3. Researchers looked at how many patients had a complete response.1

Important Safety Information

The first results included 77 patients. Updated results included all 100 patients.1,3

Was cancer still detected?

A complete response means no evidence of cancer was found during tests and examinations.

  • 62% of the 77 patients

    evaluated for FDA approval had a complete response.1

  • 71% of all 100 patients

    had a complete response, based on updated study results.3

And how long did it stay that way?

Duration of response (DOR) means how long patients continued to have no signs of cancer after their first complete response. In the FDA-label population (n=77), 58% of patients who achieved a complete response maintained their response for ≥12 months, and 40% for ≥24 months.1

In the updated results from all 100 patients3:

  • 64% of patients

    who had a complete response were estimated to still have no signs of cancer at 12 months.*

    *This percentage was estimated using the Kaplan-Meier method, which takes into account how long patients were followed in the study.

  • 26.6 months

    was the median duration of response. This means half of the patients who responded had responses that lasted longer than 26.6 months, and half had responses that lasted less.

Woman with curly grey hair and hoop earrings looking at the camera with a slight smile, lit in blue and pink light.

Not an actual patient.

My next move?

I asked about ANKTIVA.

Because I deserve a say.

When it comes to your type of bladder cancer, your questions matter. And you deserve answers.

Ask your doctor if ANKTIVA + BCG may be right for you.

Here are a few questions to bring to your next appointment.

  • Is ANKTIVA + BCG an option for my type of bladder cancer?

  • How is ANKTIVA different from the BCG treatment I’ve already had?

  • What did the ANKTIVA clinical studies show?

  • What side effects should I know about?

Man with silver hair in a dark turtleneck and jacket looking at the camera, lit in purple and pink light.

Not an actual patient.

The fight is in you.

And your next move starts with a conversation.

Ask your doctor about ANKTIVA from ImmunityBio.

is here to help patients learn about support during treatment. Through ImmunityBio CARE™, patients who qualify may get help with insurance questions, treatment costs, and access to ANKTIVA.

Get the Doctor Discussion Guide (PDF, opens in a new tab)

Important Facts about ANKTIVA® (nogapendekin alfa inbakicept-pmln)

What is ANKTIVA used for?

ANKTIVA is used with a treatment called Bacillus Calmette-Guérin (BCG) to treat adults with nonmuscle invasive bladder cancer (NMIBC) that has not responded or has stopped responding to BCG treatment alone.

What should I know before receiving ANKTIVA?

ANKTIVA may harm an unborn baby. Tell your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. If you can become pregnant, use effective birth control during treatment with ANKTIVA and for 1 week after your last dose.

What warnings should I know about ANKTIVA?

Delaying surgery to remove the bladder (cystectomy) could lead to the development of muscle invasive (or metastatic) bladder cancer, which can be fatal.

What should I tell my healthcare provider?

Before treatment with ANKTIVA, tell your doctor if you are pregnant or think you may be pregnant. After treatment with ANKTIVA, tell your doctor if you have irritable bladder symptoms or red-colored urine that lasts longer than 24 hours.

What are the side effects of ANKTIVA?

The most common side effects of ANKTIVA include changes in blood tests (increased creatinine and potassium levels); pain or burning during urination; blood in the urine; frequent or urgent urination; urinary tract infections; muscle, bone, or joint pain; chills; and fever.

The risk information provided here is not comprehensive. To learn more, talk to your doctor about ANKTIVA. You can find the FDA-approved Prescribing Information at www.ANKTIVA.com/PI (opens in a new tab) or call 1-877-ANKTIVA (1-877-265-8482).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch (opens in a new tab) or call 1-800-FDA-1088.